Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

Lenvatinib, a multitargeted tyrosine kinase inhibitor (TKI), is one of the preferred targeted drugs for the treatment of advanced hepatocellular carcinoma (aHCC). Since the REFLECT study showed that lenvatinib was noninferior to sorafenib in overall survival (OS), lenvatinib monotherapy has been wid...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Meng, Han, Jing, Shi, Juanyi, Liao, Hao, Wen, Kai, Wang, Weidong, Mui, Sintim, Li, Huoming, Yan, Yongcong, Xiao, Zhiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348321/
https://www.ncbi.nlm.nih.gov/pubmed/37457652
http://dx.doi.org/10.2147/JHC.S411806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348321/
https://www.ncbi.nlm.nih.gov/pubmed/37457652
http://dx.doi.org/10.2147/JHC.S411806

Ejemplares similares